Scarica l'app Stockscreener
11.53
0.86%
-0.10
Dopo l'orario di chiusura:
11.76
0.23
+1.99%
Precedente Chiudi:
$11.63
Aprire:
$11.55
Volume 24 ore:
721.52K
Relative Volume:
0.83
Capitalizzazione di mercato:
$881.46M
Reddito:
$54.55M
Utile/perdita netta:
$-193.57M
Rapporto P/E:
-3.9896
EPS:
-2.89
Flusso di cassa netto:
$-181.86M
1 W Prestazione:
-4.63%
1M Prestazione:
-3.68%
6M Prestazione:
-42.15%
1 anno Prestazione:
-45.33%
Intervallo 1D:
$11.26
$11.72
Intervallo di 1 settimana:
$11.12
$12.31
Portata 52W:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Confronta NRIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
11.53 | 860.06M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-17 | Iniziato | Leerink Partners | Market Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-11 | Iniziato | Jefferies | Buy |
| 2024-09-06 | Ripresa | Robert W. Baird | Outperform |
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Massachusetts Financial Services Co. MA Decreases Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.
What drives Nurix Therapeutics Inc. stock pricePowerful market insights - jammulinksnews.com
Is Nurix Therapeutics Inc. a good long term investmentExceptional trading results - Autocar Professional
Nurix Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
Hussman Strategic Advisors Inc. Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 5.4%What's Next? - MarketBeat
Janux Therapeutics Receives Buy Rating from Leerink Partners Amid Strategic Initiatives and Long-Term Growth Potential - AInvest
What analysts say about Nurix Therapeutics Inc. stockUnmatched profit potential - jammulinksnews.com
Q3 EPS Forecast for Nurix Therapeutics Raised by Analyst - MarketBeat
Janux Therapeutics (JANX) Soars 2.31% on R&D Day Announcement - AInvest
Nurix Therapeutics’ SWOT analysis: biotech stock’s pivotal trials and pipeline progress By Investing.com - Investing.com South Africa
Nurix Therapeutics’ SWOT analysis: biotech stock’s pivotal trials and pipeline progress - Investing.com Australia
When (NRIX) Moves Investors should Listen - news.stocktradersdaily.com
Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright - Yahoo Finance
NRIX: Morgan Stanley Lowers Price Target for Nurix Therapeutics - GuruFocus
A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts - Benzinga
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $34.00 at HC Wainwright - MarketBeat
H.C. Wainwright Adjusts Price Target for Nurix Therapeutics (NRI - GuruFocus
Navigating Nurix Therapeutics' Early-Stage Biotech Landscape: A Strategic SWOT Analysis - AInvest
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $30.00 by Analysts at Oppenheimer - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Issues Earnings Results - MarketBeat
Nurix Therapeutics: The BTK Disruptor With Undervalued Upside Potential - AInvest
Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors (NASDAQ:NRIX) - Seeking Alpha
UBS Group Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $26.00 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 7.8% After Earnings Beat - MarketBeat
Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest
Stifel Nicolaus Keeps Their Buy Rating on Nurix Therapeutics (NRIX) - The Globe and Mail
Piper Sandler Keeps Their Buy Rating on Nurix Therapeutics (NRIX) - The Globe and Mail
Nurix Therapeutics (NRIX) Stock Target Price Lowered by UBS Anal - GuruFocus
Mixed Moves In Health And Biotech Funds - Finimize
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):